At a day-long hearing in Washington, DC, yesterday (September 9), the House Energy and Commerce Subcommittee on Oversight and Investigations repeatedly took both Food and Drug Administration (FDA) and pharmaceutical company officials to task for failing to fully disclose clinical trial results.

The charge was led by committee chairman Rep. Joe Barton (R-Texas), a long-time FDA critic. Barton chided the agency for stonewalling committee requests for more data on studies of antidepressants in children, saying that FDA "actually stands for 'foot-dragging and alibis.'"

The subcommittee's ongoing investigation of what has–or has not–been disclosed about these drugs' efficacy and side effects was the hearing's main focus. But panelists also closely questioned FDA and drug company witnesses about whether they intended to support various proposals to create centralized registries and databases that would contain both positive and negative trial results.

Janet Woodcock, FDA's acting deputy commissioner for operations, said, "I strongly support...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?